Mark E. Davis
Plus aucun poste en cours
Profil
Mark E.
Davis is the founder of Avidity Biosciences, Inc. (founded in 2012) and ZeoDAC, Inc. (founded in 2023).
He holds the title of Director at Avidity Biosciences, Inc. and was previously an active Director at ZeoDAC, Inc. Dr. Davis is also the founder of Calando Pharmaceuticals, Inc. Dr. Davis's current jobs include being a Director at Dantari, Inc. since 2022, a Member-Experimental Therapeutics Program at the University of California, Los Angeles, and a Professor at the California Institute of Technology.
His former job was as the Chief Scientific Advisor at Insert Therapeutics, Inc. from 2000 to 2008.
Postes actifs de Mark E. Davis
| Sociétés | Poste | Début |
|---|---|---|
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA. | Corporate Officer/Principal | - |
| University of California, Los Angeles | Corporate Officer/Principal | - |
Dantari, Inc.
 Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | Directeur/Membre du Conseil | 08/12/2022 |
Anciens postes connus de Mark E. Davis
| Sociétés | Poste | Fin |
|---|---|---|
Insert Therapeutics, Inc.
 Insert Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Insert Therapeutics, Inc. researches and develops therapeutic products. It is using nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company was founded in February 2000 by Mark Davis and is located in Pasadena, CA | Corporate Officer/Principal | 08/09/2008 |
Calando Pharmaceuticals, Inc.
 Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calando Pharmaceuticals, Inc. engages in the design and development of drug-delivery-enhanced small molecule therapeutics. The company was established in 2000 and is headquartered in Pasadena, CA. | Fondateur | - |
| AVIDITY BIOSCIENCES, INC. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Insert Therapeutics, Inc.
Insert Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Insert Therapeutics, Inc. researches and develops therapeutic products. It is using nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company was founded in February 2000 by Mark Davis and is located in Pasadena, CA | Commercial Services |
Calando Pharmaceuticals, Inc.
Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calando Pharmaceuticals, Inc. engages in the design and development of drug-delivery-enhanced small molecule therapeutics. The company was established in 2000 and is headquartered in Pasadena, CA. | Health Technology |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | Health Technology |